Circulating Biomarkers in Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy is the most common genetic heart disease. Biomarkers, molecules measurable in the blood, could inform the clinician by aiding in diagnosis, directing treatment, and predicting outcomes. We present an updated review of circulating biomarkers in hypertrophic cardiomyopathy...

Descripción completa

Detalles Bibliográficos
Autores principales: Matthia, Eldon L., Setteducato, Michael L., Elzeneini, Mohammed, Vernace, Nicholas, Salerno, Michael, Kramer, Christopher M., Keeley, Ellen C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Contemporary Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9851432/
https://www.ncbi.nlm.nih.gov/pubmed/36382968
http://dx.doi.org/10.1161/JAHA.122.027618
Descripción
Sumario:Hypertrophic cardiomyopathy is the most common genetic heart disease. Biomarkers, molecules measurable in the blood, could inform the clinician by aiding in diagnosis, directing treatment, and predicting outcomes. We present an updated review of circulating biomarkers in hypertrophic cardiomyopathy representing key pathologic processes including wall stretch, myocardial necrosis, fibrosis, inflammation, hypertrophy, and endothelial dysfunction, in addition to their clinical significance.

Ejemplares similares